Compass says depression drug has long-lasting benefits
Compass Pathways' psilocybin depression therapy shows six‑month durability, sparking market optimism.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Compass Pathways reported six‑month results from its second Phase 3 trial of the psilocybin‑based compound COMP006, indicating a rapid and durable effect in treating depression. Coverage highlights the positive data, noting share price gains and the company’s plan to seek a launch in the first half of 2027.
Business Wire, Moomoo, Psychedelic Alpha, Endpoints News and STAT all reported on the trial outcomes and the upcoming year‑end filing. Next steps include the anticipated year‑end regulatory filing and a potential H1 2027 market launch, according to the statements in the reports.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 63d ago.
Quick answers
What trial phase and duration were disclosed?
Compass Pathways released six‑month data from its second Phase 3 trial of the psilocybin drug COMP006.
How did investors respond to the data?
Shares of Compass Pathways rose after the positive late‑stage trial results, as noted by Moomoo.
When does the company aim to launch the treatment?
The firm is targeting a launch in the first half of 2027, per the Psychedelic Alpha report.
Coverage (5)
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 65d ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 65d ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 65d ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 65d ago
- Compass says depression drug has long-lasting benefits STAT · 65d ago
Topics
Related trends
Novel insight into the effects of the metabolites from gut microbiota in both unmedicated depressive adolescents and mice: key roles of indole derivatives-aryl hydrocarbon receptor signaling in neurogenesis and microglial homeostasis
Recent studies link gut bacteria and microbial metabolites to brain chemistry, depression risks, and neurogenesis.
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis stock has experienced its worst day in over two decades following the failure of a critical phase 3 trial for an Avidity buyout asset.
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
Magic-mushroom compound blocks a severe side effect of chemotherapy in mice
Coverage across scientific outlets details research showing a magic-mushroom compound blocks severe chemo side effects in mice.
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.